Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 6/20 | 0.49 |
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694111 | 0.86 | RAPGEF4 (0.41) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5236778 | 0.86 | LMNA (0.43) | RAPGEF4FFAR4CA1CA2MMP1 | |
| SCHEMBL21835146 | 0.86 | RAPGEF4 (0.55) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL9826998 | 0.85 | RAPGEF4 (0.38) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL22228647 | 0.85 | RAPGEF4 (0.39) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1810783 | 0.85 | RAPGEF4 (0.38) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL12539750 | 0.85 | CYP1A2 (0.43) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL21355053 | 0.84 | POLB (0.38) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1693952 | 0.83 | LMNA (0.40) | RAPGEF4F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5384451 | 0.82 | RAPGEF4 (0.41) | RAPGEF4F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2020-09-01 | — | — | US | disclosed |
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2018-06-14 | — | — | US | disclosed |
| EP-3307272-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2018-04-18 | — | — | EP | disclosed |
| EP-2493895-B1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016198663-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2016-12-15 | — | — | WO | disclosed |
| WO-2015086693-A1 | PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
| US-8946257-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | VECTURA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. | 2013-10-31 | — | — | US | disclosed |
| US-8501735-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | PALAU PHARMA, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | ALMANSA ROSALES CARMEN (ES) | 2012-09-27 | — | — | US | disclosed |
| EP-2493895-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051452-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | RAPGEF4 2966/4885F2 2858/4885PRSS1 3624/4885 |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | RAPGEF4 2966/4885F2 2858/4885PRSS1 3624/4885 |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | RAPGEF4 2966/4885F2 2858/4885PRSS1 3624/4885 |
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK3, JAK1 | RAPGEF4 2398/4885F2 1681/4885PRSS1 2042/4885 |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | JAK2, JAK3, JAK1 | RAPGEF4 2398/4885F2 1681/4885PRSS1 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.